Mersana Therapeutics/$MRSN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mersana Therapeutics
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Ticker
$MRSN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
102
ISIN
US59045L1061
Website
MRSN Metrics
BasicAdvanced
$44M
-
-$0.60
1.30
-
Price and volume
Market cap
$44M
Beta
1.3
52-week high
$2.52
52-week low
$0.26
Average daily volume
2.8M
Financial strength
Current ratio
1.826
Quick ratio
1.759
Long term debt to equity
-26.445
Total debt to equity
-79.772
Interest coverage (TTM)
-21.07%
Profitability
EBITDA (TTM)
-75.326
Gross margin (TTM)
-113.71%
Net profit margin (TTM)
-217.64%
Operating margin (TTM)
-225.98%
Effective tax rate (TTM)
-0.57%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-30.90%
Return on equity (TTM)
5,134.17%
Valuation
Price to revenue (TTM)
1.291
Price to book
-1.44
Price to tangible book (TTM)
-1.44
Price to free cash flow (TTM)
-0.556
Free cash flow yield (TTM)
-179.95%
Free cash flow per share (TTM)
-64.08%
Growth
Revenue change (TTM)
-11.21%
Earnings per share change (TTM)
-46.85%
3-year revenue growth (CAGR)
154.29%
3-year earnings per share growth (CAGR)
-37.77%
What the Analysts think about MRSN
Analyst ratings (Buy, Hold, Sell) for Mersana Therapeutics stock.
MRSN Financial Performance
Revenues and expenses
MRSN Earnings Performance
Company profitability
MRSN News
AllArticlesVideos
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
GlobeNewsWire·3 weeks ago
Mersana Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire·1 month ago
CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mersana Therapeutics stock?
Mersana Therapeutics (MRSN) has a market cap of $44M as of June 20, 2025.
What is the P/E ratio for Mersana Therapeutics stock?
The price to earnings (P/E) ratio for Mersana Therapeutics (MRSN) stock is 0 as of June 20, 2025.
Does Mersana Therapeutics stock pay dividends?
No, Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Mersana Therapeutics dividend payment date?
Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders.
What is the beta indicator for Mersana Therapeutics?
Mersana Therapeutics (MRSN) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.